Exelixis Inc (FRA:EX9)
€ 32.75 -0.25 (-0.76%) Market Cap: 9.53 Bil Enterprise Value: 8.45 Bil PE Ratio: 22.12 PB Ratio: 4.33 GF Score: 81/100

Exelixis Inc at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 01:30PM GMT
Release Date Price: €20.71 (-0.67%)
Geoffrey Christopher Meacham
Barclays Bank PLC, Research Division - MD & Senior Research Analyst

Welcome to the second day of the Barclays Global Healthcare Conference. My name is Geoff Meacham, I'm the biopharma analyst here. My team here, too, I have Rick Harrison up on the stage with me and we're really excited to have Exelixis doing the fireside chat, and Mike Morrissey, CEO. Mike?

Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director

Good morning. Thanks for the -- well, thanks for the invite, great to be here. Yes.

Questions & Answers

Geoffrey Christopher Meacham
Barclays Bank PLC, Research Division - MD & Senior Research Analyst

So the -- I guess, let's just start with the core franchise cabozantinib has been a real success and maybe just give us, kind of, your high-level view of kind of how we got here? And kind of your general view going forward?

Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director

Okay.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot